Page 95 - Read Online
P. 95

Van Der Steen et al. Cancer Drug Resist 2018;1:230-49 I http://dx.doi.org/10.20517/cdr.2018.13                                          Page 243

               Financial support and sponsorship
               None.


               Conflicts of interest
               All authors declared that there are no conflicts of interest.


               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.

               Copyright
               © The Author(s) 2018.



               REFERENCES
               1.   Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, Kerr K, Popat S, Reck M, Senan S, Simo GV, Vansteenkiste J, Peters
                   S; ESMO Guidelines Committee. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and
                   follow-up. Ann Oncol 2016;27:V1-27.
               2.   Oda K, Matsuoka Y, Funahashi A, Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst
                   Biol 2005;1:2005.0010.
               3.   Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, Eck MJ. Structures of lung cancer-derived EGFR mutants and inhibitor
                   complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007;11:217-27.
               4.   Recondo G, Facchinetti F, Olaussen KA, Besse B, Friboulet L. Making the first move in EGFR-driven or ALK-driven NSCLC: first-
                   generation or next-generation TKI? Nat Rev Clin Oncol 2018; doi: 10.1038/s41571-018-0081-4.
               5.   Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R,
                   Kris M, Varmus H. EGF receptor gene mutations are common in lung cancers from " never smokers" and are associated
                   with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11.
               6.   Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543-50.
               7.   Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002;110:669-72.
               8.   Eck MJ, Yun C-H. Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell
                   lung cancer. Biochim Biophys Acta 2010;1804:559-66.
               9.   Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell 2002;109:275-82.
               10.  Kumar A, Petri ET, Halmos B, Boggon TJ. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J
                   Clin Oncol 2008;26:1742-51.
               11.  Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth
                   factor receptor. Cell 2006;125:1137-49.
               12.  Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
               13.  van Lengerich B, Agnew C, Puchner EM, Huang B, Jura N. EGF and NRG induce phosphorylation of HER3/ERBB3 by EGFR using
                   distinct oligomeric mechanisms. Proc Natl Acad Sci U S A 2017;114:E2836-45.
               14.  Han W, Lo HW. Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor
                   subcellular locations. Cancer Lett 2012;318:124-34.
               15.  Walker F, Kato A, Gonez LJ, Hibbs ML, Pouliot N, Levitzki A, Burgess AW. Activation of the Ras/mitogen-activated protein
                   kinase pathway by kinase-defective epidermal growth factor receptors results in cell survival but not proliferation. Mol Cell Biol
                   1998;18:7192-204.
               16.  Schnidar H, Eberl M, Klingler S, Mangelberger D, Kasper M, Hauser-Kronberger C, Regl G, Kroismayr R, Moriggl R, Sibilia M,
                   Aberger F. Epidermal growth factor receptor signaling synergizes with hedgehog/GLI in oncogenic transformation via activation of the
                   MEK/ERK/JUN pathway. Cancer Res 2009;69:1284-92.
               17.  Engelman JA, Jänne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, Cichowski K, Johnson BE, Cantley LC. ErbB-3 mediates
                   phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A 2005;102:3788-
                   93.
               18.  Park OK, Schaefer TS, Nathans D. In vitro activation of Stat3 by epidermal growth factor receptor kinase. Proc Natl Acad Sci U S A
                   1996;93:13704-08.
               19.  Anderson D, Koch C, Grey L, Ellis C, Moran M, Pawson T. Binding of SH2 domains of phospholipase C gamma 1, GAP, and Src to
                   activated growth factor receptors. Science 1990;250:979-82.
               20.  Coker KJ, Staros J V, Guyer CA. A kinase-negative epidermal growth factor receptor that retains the capacity to stimulate DNA
   90   91   92   93   94   95   96   97   98   99   100